DSIP
Last reviewed
Also known as: Delta Sleep-Inducing Peptide
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide studied for improving deep sleep quality and reducing nighttime awakenings in people with chronic insomnia.
Modulates sleep-wake cycle. Promotes delta-wave (deep) sleep phases. Interacts with GABA, serotonin, and opioid pathways.
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
§ AI Reference Summary
DSIP (also known as Delta Sleep-Inducing Peptide) is a prominently researched experimental compound classified strictly within the Sleep Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it modulates sleep-wake cycle. Promotes delta-wave (deep) sleep phases. Interacts with GABA, serotonin, and opioid pathways. with a documented biological half-life of roughly 0.13 hours, In preclinical investigative trials and independent academic studies, researchers utilizing DSIP have documented significant, quantifiable biological outcomes, primarily focusing on improved sleep quality, stress reduction. Typical research protocols investigate administering 100 to 100mcg via subq pathways 7x/wk. However, it is critically important to understand that while DSIP demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
§ Mechanism of Action
Modulates sleep-wake cycle. Promotes delta-wave (deep) sleep phases. Interacts with GABA, serotonin, and opioid pathways.
§ Primary Benefits
- 1Improved sleep quality
- 2stress reduction
§ Clinical Evidence
DSIP delta sleep promotion in chronic insomniacs
Schneider-Helmert & Schoenenberger: DSIP administered IV to chronic insomniacs decreased nocturnal awakenings, reduced sleep latency, and increased total NREM sleep time.
ModerateDSIP normalizes sleep in elderly insomniacs
DSIP normalizes sleep architecture in middle-aged and elderly chronic insomniacs, with improvements maintained during follow-up week after treatment cessation.
ModerateSynthetic DSIP improves disturbed human sleep
Schneider-Helmert (Experientia): Longer sleep duration, fewer interruptions, and increased REM sleep documented without daytime sedation or side effects.
ModerateRepeated DSIP administration and sleep structure normalization
Study demonstrating that repeated DSIP administration produces cumulative buildup effects, progressively normalizing disturbed sleep patterns.
ModerateTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Therapeutic peptides, including BPC-157 and TB-500, were found to modulate molecular signaling networks influencing tissue regeneration and inflammation resolution in a 2026 review. The research highlighted their mechanistic potential for orthopaedic applications, noting a current lack of clinical trials.
EmergingDomain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages.
A 2025 study demonstrated that a novel domain-specific information preservation framework significantly outperformed existing methods in imputing missing neuroimage data and identifying Alzheimer's disease status. The dual-stage model successfully captured modality-specific details to improve diagnostic accuracy.
EmergingPichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
A 2024 preclinical study demonstrated that a DSIP-CBBBP fusion peptide modulated neurotransmitter levels and exhibited greater restorative effects on sleep and neurotransmitter imbalance compared to DSIP alone in an insomnia mouse model.
PreclinicalSensing the Bactericidal and Bacteriostatic Antimicrobial Mode of Action Using Raman Deuterium Stable Isotope Probing (DSIP) in Escherichia coli.
A 2024 study demonstrated that Raman deuterium stable isotope probing can successfully discriminate between bactericidal and bacteriostatic antibiotic modes of action in Escherichia coli. Researchers found that changes in the C-D band intensity serve as a quantifiable marker for early identification of antimicrobial activity.
PreclinicalElectronic Prediction of Chemical Contaminants in Aroma of Brewed Roasted Coffee and Quantification of Acrylamide Levels.
A 2024 study demonstrated that an electronic nose device successfully predicted chemical contaminants, including acrylamide and 5-hydroxymethylfurfural, in roasted espresso coffee. Researchers found a strong correlation between the device's electronic signals, sensory defects like a burnt smell, and specific contaminant levels.
PreclinicalPractical N-to-C peptide synthesis with minimal protecting groups.
A 2023 study demonstrated a novel N-to-C peptide synthesis strategy utilizing catalytic thioacid formation and oxidative bond formation with minimal protecting groups. Researchers found this method effectively suppressed epimerization and successfully synthesized the nonapeptide DSIP, offering a cleaner alternative to traditional synthesis.
Preclinical§ Safety Profile
Limited modern data. Most studies from the 1980s-90s. Safety profile incompletely defined.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
RouteSubQ
Dose Range100–100 mcg
Frequency7x/wk
Timing30 min before bed
Cycle Length4–4 weeks
BAC Water2.5 ml / 5mg vial
Very short half-life. Take immediately before sleep. Cycle to avoid tolerance.
§ Pharmacokinetics
⏱️ Half-Life: 8min
Plasma concentration over time§ Regulatory
🇺🇸USA
Research Only🇨🇦Canada
Research Only🇬🇧UK
Unregulated🇪🇺EU
Unregulated🇦🇺Australia
Research OnlyLast updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
§ Expected Outcomes
Week 1
Improved sleep onset and delta-wave sleep depth
Weeks 2–4
More restful sleep; potential pain modulation via opioid pathways
Month 2–3
Circadian rhythm stabilization; stress resilience improvement
Long-term
Effects require cycling; cumulative normalization of sleep architecture
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Headache | ~3% of users | mild |
Morning grogginess (wrong timing) Take 30 min before sleep, not earlier | ~5% of users | mild |
Where to Source DSIP for Research
Finding verified, high-purity DSIP requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified DSIP✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Reconstitution CalculatorCalculate reconstitution for DSIP →
Compare ToolCompare DSIP to similar peptides →
Frequently Asked Questions
§ Community Stacks
Cite This Page
Free Download
2026 Peptide Stack Cheat Sheet
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author
Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...
View Full ProfileLast fact-checked: · PeptiDex Editorial Team
⚠ Educational only · Not medical advice · Most peptides are research-only / not FDA-approved